• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·RPID
Share

Rapid Micro Biosystems, Inc. Stocks

$ 2.09Last Updated 16.07.2026

Issuer Rating

2/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

$ 93.82M

$ 2.09
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

17.07.2026 08:30

Lilly to Acquire Psychedelic Drug Developer for $3.8 Billion. Are There Any Prospects?

17.07.2026 07:30

Netflix is expecting a slowdown in revenue growth for the second consecutive quarter. Its stock plummeted 8%.

17.07.2026 02:57

The release of Google's cutting-edge AI model has been delayed by months — Bloomberg. Shares fell

17.07.2026 01:40

Alphabet and other tech stocks dragged down the entire market: the Nasdaq index fell 1.5%

17.07.2026 01:10

Trump Media will charge traders for quick access to Trump's posts

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026